Tumor specific delivery and therapy mediate by integrin &#x03B2;6-target immunoliposomes for &#x03B2;6-siRNA in colon carcinoma

Liu Song; Zhang Fan; Niu Jun; Liang Benjia; Li Zequn; Wang Xilong; Jia Zhongming; Han yong; Wang Xiaohong; Cheng Kai; Yang Zhenlin

doi:10.18632/oncotarget.13209

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Tumor specific delivery and therapy mediate by integrin β6-target immunoliposomes for β6-siRNA in colon carcinoma

Liu Song _, Zhang Fan, Niu Jun, Liang Benjia, Li Zequn, Wang Xilong, Jia Zhongming, Han yong, Wang Xiaohong, Cheng Kai and Yang Zhenlin

PDF | HTML | How to cite

Oncotarget. 2016; 7:85163-85175. https://doi.org/10.18632/oncotarget.13209

Metrics: PDF 2353 views | HTML 2495 views | ?

Abstract

Liu Song1, Zhang Fan2, Niu Jun3, Liang Benjia3, Li Zequn3, Wang Xilong1, Jia Zhongming1, Han yong1, Wang Xiaohong1, Cheng Kai1, Yang Zhenlin1

1Department of Thyroid & Breast Surgery, Binzhou Medical College Affiliated Hospital, Binzhou 256600, Shandong, PR China

2Department of Oncology, Binzhou Medical College Affiliated Hospital, Binzhou 256600, Shandong, PR China

3Department of Hepatobiliary Surgery, Qilu Hospital of Shandong University, Jinan 250012, Shandong, PR China

Correspondence to:

Yang Zhenlin, email: [email protected]

Keywords: colon carcinoma, integrinβ6, target therapy, immunoliposomes, siRNA

Received: June 06, 2016 Accepted: October 21, 2016 Published: November 08, 2016

ABSTRACT

Adjuvant chemotherapy does not achieve the desired therapeutic efficacy in colon cancer as a result of the deficient reaction. Gene therapy using small interfering RNAs (siRNAs) delivered by target delivering system represents a potent and specific strategy in tumor therapy. Integrinβ6 is exclusively expressed in malignant colonic epithelia, associated with the progression, metastasis, and chemotherapeutic resistance of colon cancer. Accordingly, designing an efficient and targeted delivery system for β6-siRNA could be a potential approach to improve therapeutic efficacy of colon cancer. Here, we designed the Integrinβ6 target immunoliposomes for highly efficient and selective delivery of β6-siRNA in colon cancer, which consequently resulted in greatly growth suppression, invasion and metastasis of colon cancer cells. Moreover, it was able to greatly inhibit the tumor growing in vivo.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 13209

Publication Alerts

Research Papers:

Tumor specific delivery and therapy mediate by integrin β6-target immunoliposomes for β6-siRNA in colon carcinoma

Abstract